

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of Repeat Doses of SUSTOL in Adults
Details : Sustol (Granisetron) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Sustol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Product Name : Sancuso
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Cumberland Pharmaceuticals Acquires Sancuso® From Kyowa Kirin North America
Details : Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities...
Product Name : Sancuso
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastroparesis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Heron Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Heron Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Tri-Service General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2015
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Tri-Service General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Granisetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2013
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
